Top

Published in:

Open Access 01-10-2024 | NSCLC | Research

Spatial cell interplay networks of regulatory T cells predict recurrence in patients with operable non-small cell lung cancer

Authors: Siqi Cai, Guanqun Yang, Mengyu Hu, Chaozhuo Li, Liying Yang, Wei Zhang, Jujie Sun, Fenghao Sun, Ligang Xing, Xiaorong Sun

Published in: Cancer Immunology, Immunotherapy | Issue 10/2024

Abstract

Background

The interplay between regulatory T cells (Tregs) and neighboring cells, which is pivotal for anti-tumor immunity and closely linked to patient prognosis, remains to be fully elucidated.

Methods

Tissue microarrays of 261 operable NSCLC patients were stained by multiplex immunofluorescence (mIF) assay, and the interaction between Tregs and neighboring cells in the tumor microenvironment (TME) was evaluated. Employing various machine learning algorithms, we developed a spatial immune signature to predict the prognosis of NSCLC patients. Additionally, we explored the interplay between programmed death-1/programmed death ligand-1 (PD-1/PD-L1) interactions and their relationship with Tregs.

Results

Survival analysis indicated that the interplay between Tregs and neighboring cells in the invasive margin (IM) and tumor center was associated with recurrence in NSCLC patients. We integrated the intersection of the three algorithms to identify four crucial spatial immune features [P_(CD8⁺_{Treg to CK)} in IM, P_(CD8⁺_{Treg to CD4)} in IM, N_(CD4⁺_{Treg to CK)} in IM, N_(CD4⁺_{Tcon to CK)} in IM] and employed these characteristics to establish SIS, an independent prognosticator of recurrence in NSCLC patients [HR = 2.34, 95% CI (1.53, 3.58), P < 0.001]. Furthermore, analysis of cell interactions demonstrated that a higher number of Tregs contributed to higher PD-L1⁺ cells surrounded by PD-1⁺ cells (P < 0.001) with shorter distances (P = 0.004).

Conclusion

We dissected the cell interplay network within the TME, uncovering the spatial architecture and intricate interactions between Tregs and neighboring cells, along with their impact on the prognosis of NSCLC patients.

Available only for authorised users

Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148. https://doi.org/10.1016/j.immuni.2004.07.017CrossRefPubMed

Galon J, Angell HK, Bedognetti D, Marincola FM (2013) The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39:11–26. https://doi.org/10.1016/j.immuni.2013.07.008CrossRefPubMed

Yu P, Fu YX (2006) Tumor-infiltrating T lymphocytes: friends or foes? Lab Investig 86:231–245. https://doi.org/10.1038/labinvest.3700389CrossRefPubMed

Oliveira G, Wu CJ (2023) Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer 23:295–316. https://doi.org/10.1038/s41568-023-00560-yCrossRefPubMedPubMedCentral

Alcover A, Alarcón B, Di Bartolo V (2018) Cell biology of T cell receptor expression and regulation. Annu Rev Immunol 36:103–125. https://doi.org/10.1146/annurev-immunol-042617-053429CrossRefPubMed

Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F, Woller N (2018) CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cellular Mol Life Sci 75:689–713. https://doi.org/10.1007/s00018-017-2686-7CrossRef

Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W (2018) CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 18:635–647. https://doi.org/10.1038/s41577-018-0044-0CrossRefPubMed

Bedoui S, Heath WR, Mueller SN (2016) CD4(+) T-cell help amplifies innate signals for primary CD8(+) T-cell immunity. Immunol Rev 272:52–64. https://doi.org/10.1111/imr.12426CrossRefPubMed

Vyas M, Requesens M, Nguyen TH, Peigney D, Azin M, Demehri S (2022) Natural killer cells suppress cancer metastasis by eliminating circulating cancer cells. Front Immunol 13:1098445. https://doi.org/10.3389/fimmu.2022.1098445CrossRefPubMed

10.

Piccirillo CA, Thornton AM (2004) Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. Trends Immunol 25:374–380. https://doi.org/10.1016/j.it.2004.04.009CrossRefPubMed

11.

Jiang M, Wu C, Zhang L et al (2021) FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002339CrossRefPubMedPubMedCentral

12.

Kinoshita T, Muramatsu R, Fujita T et al (2016) Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer. Annals Oncol 27:2117–2123. https://doi.org/10.1093/annonc/mdw319CrossRef

13.

Moreno Ayala MA, Campbell TF, Zhang C, Dahan N, Bockman A, Prakash V, Feng L, Sher T, DuPage M (2023) CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity. Immunity 56:1613–30.e5. https://doi.org/10.1016/j.immuni.2023.06.003CrossRefPubMed

14.

Nagl S, Haas M, Lahmer G, Büttner-Herold M, Grabenbauer GG, Fietkau R, Distel LV (2016) Cell-to-cell distances between tumor-infiltrating inflammatory cells have the potential to distinguish functionally active from suppressed inflammatory cells. Oncoimmunology 5:e1127494. https://doi.org/10.1080/2162402x.2015.1127494CrossRefPubMedPubMedCentral

15.

Feichtenbeiner A, Haas M, Büttner M, Grabenbauer GG, Fietkau R, Distel LV (2014) Critical role of spatial interaction between CD8⁺ and Foxp3⁺ cells in human gastric cancer: the distance matters. Cancer Immunol Immunother 63:111–119. https://doi.org/10.1007/s00262-013-1491-xCrossRefPubMed

16.

Kumagai S, Koyama S, Itahashi K et al (2022) Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 40:201–18.e9. https://doi.org/10.1016/j.ccell.2022.01.001CrossRefPubMed

17.

Kumagai S, Togashi Y, Kamada T et al (2020) The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 21:1346–1358. https://doi.org/10.1038/s41590-020-0769-3CrossRefPubMed

18.

Kamada T, Togashi Y, Tay C et al (2019) PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA 116:9999–10008. https://doi.org/10.1073/pnas.1822001116CrossRefPubMedPubMedCentral

19.

Mlecnik B, Bindea G, Kirilovsky A et al (2016) The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 8:32726. https://doi.org/10.1126/scitranslmed.aad6352CrossRef

20.

Donnem T, Kilvaer TK, Andersen S et al (2016) Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Ann Oncol 27:225–232. https://doi.org/10.1093/annonc/mdv560CrossRefPubMed

21.

Carstens JL, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A, Allison JP, LeBleu VS, Kalluri R (2017) Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun 8:15095. https://doi.org/10.1038/ncomms15095CrossRefPubMedPubMedCentral

22.

Kornepati AVR, Vadlamudi RK, Curiel TJ (2022) Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer 22:174–189. https://doi.org/10.1038/s41568-021-00431-4CrossRefPubMedPubMedCentral

23.

Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034. https://doi.org/10.1084/jem.192.7.1027CrossRefPubMedPubMedCentral

24.

Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7–H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8:3284. https://doi.org/10.1126/scitranslmed.aad7118CrossRef

25.

Gong J, Chehrazi-Raffle A, Reddi S, Salgia R (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6:8. https://doi.org/10.1186/s40425-018-0316-zCrossRefPubMedPubMedCentral

26.

Saito T, Nishikawa H, Wada H et al (2016) Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med 22:679–684. https://doi.org/10.1038/nm.4086CrossRefPubMed

27.

Scott EN, Gocher AM, Workman CJ, Vignali DAA (2021) Regulatory T cells: barriers of immune infiltration into the tumor microenvironment. Front Immunol 12:702726. https://doi.org/10.3389/fimmu.2021.702726CrossRefPubMedPubMedCentral

28.

deLeeuw RJ, Kost SE, Kakal JA, Nelson BH (2012) The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18:3022–3029. https://doi.org/10.1158/1078-0432.Ccr-11-3216CrossRefPubMed

29.

Sawant DV, Yano H, Chikina M et al (2019) Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol 20:724–735. https://doi.org/10.1038/s41590-019-0346-9CrossRefPubMedPubMedCentral

30.

Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL (2007) A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13:4345–4354. https://doi.org/10.1158/1078-0432.Ccr-07-0472CrossRefPubMed

31.

Nishikawa H, Koyama S (2021) Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002591CrossRefPubMedPubMedCentral

32.

Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ (2007) Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27:635–646. https://doi.org/10.1016/j.immuni.2007.08.014CrossRefPubMed

33.

Frafjord A, Buer L, Hammarström C, Aamodt H, Woldbæk PR, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2021) the immune landscape of human primary lung tumors is Th2 skewed. Front Immunol 12:764596. https://doi.org/10.3389/fimmu.2021.764596CrossRefPubMedPubMedCentral

34.

Zhang X, Brunner T, Carter L et al (1997) Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 185:1837–1849. https://doi.org/10.1084/jem.185.10.1837CrossRefPubMedPubMedCentral

35.

Fang Y, Yu S, Ellis JS, Sharav T, Braley-Mullen H (2010) Comparison of sensitivity of Th1, Th2, and Th17 cells to Fas-mediated apoptosis. J Leukoc Biol 87:1019–1028. https://doi.org/10.1189/jlb.0509352CrossRefPubMedPubMedCentral

36.

Huang D, Chen X, Zeng X et al (2021) Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer. Nat Immunol 22:865–879. https://doi.org/10.1038/s41590-021-00939-9CrossRefPubMed

37.

Acúrcio RC, Pozzi S, Carreira B et al (2022) Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment. J Immunother Cancer. https://doi.org/10.1136/jitc-2022-004695CrossRefPubMedPubMedCentral

38.

Sánchez-Magraner L, Gumuzio J, Miles J et al (2023) Functional engagement of the PD-1/PD-L1 complex but not PD-L1 expression is highly predictive of patient response to immunotherapy in non-small-cell lung cancer. J Clin Onco 41:2561–2570. https://doi.org/10.1200/jco.22.01748CrossRef

39.

Duraiswamy J, Freeman GJ, Coukos G (2013) Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Can Res 73:6900–6912. https://doi.org/10.1158/0008-5472.Can-13-1550CrossRef

40.

Jacobs JF, Idema AJ, Bol KF et al (2009) Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol 11:394–402. https://doi.org/10.1215/15228517-2008-104CrossRefPubMedPubMedCentral

41.

Amarnath S, Mangus CW, Wang JC et al (2011) The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 3:111ra20. https://doi.org/10.1126/scitranslmed.3003130CrossRef

42.

Yoshida K, Okamoto M, Sasaki J et al (2020) Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. BMC Cancer 20:25. https://doi.org/10.1186/s12885-019-6499-yCrossRefPubMedPubMedCentral

43.

Toor SM, Syed Khaja AS, Alkurd I, Elkord E (2018) In-vitro effect of pembrolizumab on different T regulatory cell subsets. Clin Exp Immunol 191:189–197. https://doi.org/10.1111/cei.13060CrossRefPubMed

44.

Wang Z, Wang Y, Yang T et al (2021) Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. Brief Bioinform. https://doi.org/10.1093/bib/bbab032CrossRefPubMedPubMedCentral

45.

Lai Y, Lin P, Lin F, Chen M, Lin C, Lin X, Wu L, Zheng M, Chen J (2022) Identification of immune microenvironment subtypes and signature genes for Alzheimer’s disease diagnosis and risk prediction based on explainable machine learning. Front Immunol 13:1046410. https://doi.org/10.3389/fimmu.2022.1046410CrossRefPubMedPubMedCentral

46.

Errington N, Iremonger J, Pickworth JA et al (2021) A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. EBioMedicine 69:103444. https://doi.org/10.1016/j.ebiom.2021.103444CrossRefPubMedPubMedCentral

Title: Spatial cell interplay networks of regulatory T cells predict recurrence in patients with operable non-small cell lung cancer
Authors: Siqi Cai
Guanqun Yang
Mengyu Hu
Chaozhuo Li
Liying Yang
Wei Zhang
Jujie Sun
Fenghao Sun
Ligang Xing
Xiaorong Sun
Publication date: 01-10-2024
Publisher: Springer Berlin Heidelberg
Keywords: NSCLC
NSCLC
Published in: Cancer Immunology, Immunotherapy / Issue 10/2024
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-024-03762-x

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

17-09-2024
Prostate Cancer
News

Adding radium-223 to first-line enzalutamide significantly improves the survival of patients with bone metastatic castration-resistant prostate cancer.

19-09-2024
Diagnostics in Oncology
News

No OS benefit of adding preoperative CRT in gastric cancer

17-09-2024
Gastric Cancer
News

T-DXd supported for breast cancer with brain metastases

17-09-2024
Breast Cancer
News

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Spatial cell interplay networks of regulatory T cells predict recurrence in patients with operable non-small cell lung cancer

Abstract

Background

Methods

Results

Conclusion

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2024

Deciphering the interplay of HPV infection, MHC-II expression, and CXCL13+ CD4+ T cell activation in oropharyngeal cancer: implications for immunotherapy

Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs

Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature

DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer

Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent

Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma